Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03675893 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06147960 | Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer(EPIcol) | recruiting | — | 180 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 22, 2026 |
| clinicaltrials |
| NCT07653503 | Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)(NEOLYNC) | recruiting | Phase 1 | 12 | University Medical Center GroningenOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07625943 | HYPOfractionated RadioTherapy in Cervical Cancer(HYPORT-CC) | recruiting | N/A | 396 | All India Institute of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07022470 | Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT). | recruiting | Phase 2 | 41 | Stanford UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06825689 | Unidos Contra el VPH(Unidos) | recruiting | N/A | 735 | University of Texas at AustinOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07220239 | Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome(SCREEN-CUP) | recruiting | N/A | 25 | Jessica D. St. Laurent, MDOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations | recruiting | Phase 1 / Phase 2 | 178 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05819892 | Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | recruiting | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07107334 | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05916196 | [18F]FES PET/.CT in Uterine Cancer | recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06914297 | TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC | recruiting | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06024109 | Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy(BARHYSTER) | recruiting | — | 132 | Aesculap AGINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | recruiting | Phase 2 | 80 | MacroGenicsINDUSTRY | 3 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06042543 | Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs(EASTER) | recruiting | N/A | 3,200 | International Agency for Research on CancerOTHER | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06680739 | Single cEll pRofiling PErsistaNce To ImmuNothErapy(SERPENTINE) | recruiting | Phase 2 | 60 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07286188 | Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | recruiting | Phase 4 | 40 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05743517 | Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) | recruiting | N/A | 192 | Northwestern UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06153667 | Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)(BETTER-UAE) | recruiting | — | 100 | Merit Medical Systems, Inc.INDUSTRY | 3 | May 29, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07472153 | PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer | recruiting | Phase 2 / Phase 3 | 120 | N.N. Alexandrov National Cancer CentreOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT07368205 | Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging(PRSTEC_multipr) | recruiting | — | 350 | University Hospital Hradec KraloveOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07597083 | Biofeedback-Assisted Pelvic Floor Rehabilitation for Radiation-Induced Sexual Dysfunction in Cervical Cancer Survivors | recruiting | N/A | 60 | Beni-Suef UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07595224 | Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer(PostOP HYPOCxE) | recruiting | N/A | 120 | Siriraj HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features(RAINBO) | recruiting | Phase 2 / Phase 3 | 1,615 | Leiden University Medical CenterOTHER | 4 | May 15, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors(N01-A-PICIT-GT) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07400536 | A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT | recruiting | Phase 3 | 378 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04743674 | Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment | recruiting | — | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 2 | May 12, 2026 | clinicaltrials |
| NCT05979610 | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies(Reiki-Brachy) | recruiting | Phase 2 | 70 | University of UtahOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05544084 | Adaptation and Implementation of a Patient Navigation Program for Cervical Cancer Screening Across Contexts in Senegal | recruiting | N/A | 901 | University of Illinois at ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05049538 | Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers | recruiting | — | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06266338 | Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) | recruiting | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06466382 | OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy(OVPrecision) | recruiting | N/A | 60 | Swiss GO Trial GroupNETWORK | 1 | May 5, 2026 | clinicaltrials |
| NCT07345897 | Emergency Department-based Cervical Cancer Screening Through Self-sampling | recruiting | N/A | 200 | University of RochesterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07378098 | to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia | recruiting | Phase 3 | 254 | JW PharmaceuticalINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT05440760 | Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy | recruiting | N/A | 20 | University of ArkansasOTHER | 1 | Apr 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 22, 2026source: clinicaltrials